UNIQURE NV CMO Buys Shares Amid FDA Milestone Hopes, Signals Long‑Term Confidence in Gene‑Therapy Pipeline

Insider Activity at UNIQURE NV: A Closer Look at Chief Medical Officer Transactions

1. Recent Transaction Context On October 30, 2026, Chief Medical Officer Abi‑Saab Walid executed a “buy” of 18,750 ordinary shares at the current market price of €20.80. The purchase is part of a performance‑based restricted share unit (PRSU) grant that will vest only after regulatory milestones are met, indicating a long‑term commitment to the company’s gene‑therapy pipeline. While the trade itself is modest in size, the timing—just days after a 8.33 % weekly rise in the stock—suggests that the CMO is aligning his interests with shareholders as the company approaches key FDA milestones for its Huntington’s disease therapy.

2. Implications for Investors Walid’s purchase reflects confidence in UNIQURE’s prospects, especially given the company’s recent FDA acceptance of its investigational biologics licence. The PRSU structure means the shares will only vest when the therapy moves beyond Phase I/II, which could occur in 2027‑28. For investors, this adds a layer of upside potential that is not captured in the current share price. However, the negative price‑earnings ratio (-6.17) and the company’s negative earnings highlight that the market is still waiting for a commercial launch. The insider buy may serve as a signal that executives see value in the long‑term trajectory, but it does not guarantee immediate profitability.

3. Historical Insider Patterns of Abi‑Saab Walid Over the past nine months, Walid has alternated between buying and selling ordinary shares and stock options. He sold large blocks in March and May (e.g., 20,000 shares at €25.10 in May), likely to meet personal liquidity needs or to balance his option positions. His buys—such as the 25,000‑share purchase in May at €5.59—have been made at discounted prices, a common practice for executives receiving grant‑based compensation. The pattern shows that while he periodically liquidates holdings, he consistently reinvests in the company, especially when share prices are low, suggesting a belief in long‑term upside. The most recent buy, part of a PRSU, underscores a shift from short‑term trading to a performance‑linked stake that will only vest upon regulatory success.

4. Company‑Wide Insider Activity CEO Matthew Kapusta’s recent transactions—large buys and sells—indicate a more active trading strategy that may reflect short‑term market timing. In contrast, other senior executives (e.g., Chief Legal Officer, Chief Financial Officer) have largely sold shares or exercised options, which may reflect personal cash flow needs rather than strategic sentiment. The concentration of buying activity among the CMO and CEO may suggest that the core leadership sees a favorable outlook for UNIQURE’s gene‑therapy portfolio, especially in light of the FDA’s priority review designation.

5. Forward‑Looking Perspective For investors, Walid’s PRSU buy is a subtle but meaningful endorsement of the company’s long‑term strategy. It aligns executive equity with shareholder value and could provide an additional incentive for the management team to hit the critical regulatory milestones in 2027–28. The overall insider activity, while mixed, points to a leadership team that is actively managing their holdings while remaining invested in UNIQURE’s future. As the FDA review proceeds and clinical data accumulates, the market may reward this conviction with a stronger price trajectory, turning the current negative P/E into a positive outlook for the gene‑therapy market.